Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04326868
Other study ID # 0084/2019/PR/SG/CNER
Secondary ID CEI- 007/2019
Status Completed
Phase Phase 4
First received
Last updated
Start date November 11, 2019
Est. completion date January 30, 2021

Study information

Verified date July 2021
Source Centre de Recherche Médicale de Lambaréné
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Soil-transmitted helminths (STHs) infections are common in subtropics and mostly affect the poorest communities, with an impact on human health in many parts of the world. In 2017, World Health organization (WHO) reports more than 1.5 billion people are infected with soil-transmitted helminths worldwide, including 568 million school-age children who need treatment and preventive interventions. Preventive chemotherapy and periodic mass administration with benzimidazoles (BZ) [albendazole (ABZ) and mebendazole (MBZ)] are used to control these parasites. However, rapid reinfection with Ascaris lumbricoides within six months after a completed treatment has been reported, while the reinfection with hookworms is slow. Similarly, the efficacy of these drugs on Trichuris trichiura cure rate is poor. After many years of use of this drug class, there is an increase possibility that BZ resistance could develop. This resistance may occur due to single nucleotide polymorphisms (SNPs) in the β-tubulin gene at positions 167, 198 or 200, as has been reported in animals. Little data exist to show whether any of these polymorphisms do influence the BZ efficacy against STH in humans. The present study will develop methods to look for molecular evidence of BZ drug resistance in human population in order to support the investigation of the control and elimination of neglected tropical diseases (NTDs) in our communities.


Description:

A Randomized Controlled Clinical Trial (RCT) cohort study, to evaluate the efficacy and safety of three benzimidazole derivates drug (Albendazole, Mebendazole, Albendazole Mebendazole, and Albendazole-Pyrantel) to treat major STH in school aged children from Lambaréné and surroundings. After obtaining informed consent from parents or guardians, stool samples will be collected, for infectious status. If positive the participant will be treated with either drug combination. The efficacy and SNP frequencies will be assessed at weeks 3 and 6 post treatment Description of study population Children of school and preschool age (2 to 17 years old) living in Lambaréné and the surrounding areas are eligible. The choice of school and preschool-aged children is based on the fact that they constitute the main population at risk of infection. In addition, most of the resources available for public health interventions in many endemic areas of soil-transmitted helminths target this group as a cost-effective method for reaching a large part of the population. The previous analysis of patient cohort reported a success rate of 61% multispecies prevalence amongst children in the study area and considering a significance level of 95% confidence interval (α =5%) and a minimum power of 80%, the investigators will have to include a total of 255 participants in the study


Recruitment information / eligibility

Status Completed
Enrollment 255
Est. completion date January 30, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years to 17 Years
Eligibility Inclusion Criteria: - Living in Lambaréné and surrounding areas - Written informed consent or assent - Microscopy positive for any major Soil-Transmitted helminths Exclusion Criteria: - Microscopy negative for any STH - Pregnant women - Do not be available for followed up.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Benzimidazole Anthelmintic
The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.

Locations

Country Name City State
Gabon Centre de Recherches Médicales de Lammbaréné Lambaréné Moyen- Ogooué

Sponsors (1)

Lead Sponsor Collaborator
Centre de Recherche Médicale de Lambaréné

Country where clinical trial is conducted

Gabon, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of eggs rate reduction . The assessment of efficacy will be the level of the eggs rate reduction . The assessment will be done at weeks 3 and 6 and a different treatment regimen will be compared according to protocol and intention to treat.
This evaluation will be based on the same parasitological examinations carried out at the beginning. Using polymerase chain reaction(PCR) for a better, appreciation of the efficacy of Benzimidazole.
three weeks to six weeks
Primary Assessment of cure rate The assessment of efficacy as a cure rate, based on the absence of eggs at three and six weeks post treatment, using microscopy and PRC examination. three weeks to six weeks
Secondary The assessment of safety The adverse events due to a drug intake and the frequency of single nucleotide polymorphisms (SNPs) before and after treatment in each group.The safety of administration of Benzimidazole will be evaluated primarily clinically. The safety will be evaluated within 24 hours and at any unscheduled visit or at week 3 and week 6 to record any symptoms that occur after the drug has been administered. three to six weeks.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Terminated NCT00319150 - REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial Phase 3
Completed NCT00563875 - Laboratory Aspirin Resistance in Diabetics and Non-Diabetics N/A
Completed NCT00389129 - Danish Aspirin Resistance Trial - Pilot Study N/A
Terminated NCT00193947 - An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy Phase 4
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT01039480 - Aspirin and Clopidogrel Resistance Study N/A
Recruiting NCT05310370 - HRD and Resistance to PAPPi in EOC Patients
Active, not recruiting NCT00457236 - Effect of Clopidogrel Loading and Risk of PCI N/A
Completed NCT02792816 - Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar N/A
Completed NCT01386476 - (18F)FCWAY and the Blood-Brain Barrier
Recruiting NCT04990596 - Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)
Recruiting NCT03401957 - The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment N/A
Completed NCT04404582 - Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection
Completed NCT02401204 - Bacterial Transmission Dynamics Study
Completed NCT03114098 - Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs N/A
Recruiting NCT03361267 - Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection N/A
Completed NCT00302913 - Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition N/A
Completed NCT04833231 - The Relationship Between Renal Functions and Multi Drug Resistant Organisms
Completed NCT00965042 - Effect of Ceftobiprole on Human Intestinal Microflora Phase 1